SAF-189 is under clinical development by Fochon Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SAF-189’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SAF-189 overview

SAF-189 is under development for the treatment of ALK- positive cancers like non small cell lung cancer and lymphoma. It is administered through oral route in the form of capsule. The drug candidate acts by targeting the ALK Kinase and receptor tyrosine kinase c Ros oncogene 1 (ROS1).

Fochon Pharmaceutical overview

Chongqing Fochon Pharmaceutical Co., Ltd. is engaged in the research and development of chemical drugs.

For a complete picture of SAF-189’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.